
An exciting year and time for GCA and PMR treatment!
- Tocilizumab (IL-6i)
- Secukinumab (IL-17i)
- Sarilumab (IL-6i)
- Mavrilimumab (GM-CSF receptor mAb)
- Tofacitinib (JAKinib)
@RheumNow #RNL2023 https://t.co/d0T2RAssFY
Links:
19-03-2023